Although early detection has reduced mortality from prostate cancer, there is no curative treatment for advanced disease 1 . Consequently, one in 30 men is expected to die from metastatic prostate cancer 1,2 . Nevertheless, our current understanding of the mechanisms that drive progression and metastasis is limited. Hyperactivation of Ras effector pathways (the extracellular signal-regulated kinase (ERK) and AKT kinase pathways) have been proposed to promote prostate cancer progression [3] [4] [5] [6] . However, whereas AKT is activated by loss of the gene encoding phosphatase and tensin homolog, it is unclear how ERK is activated in this tumor type. KRAS and BRAF mutations are present in a subset of tumors from Japanese and Korean individuals, but are rare in American and European populations [7] [8] [9] .
Primary human prostate epithelial cells (PrECs) are immortalized by introducing Simian virus 40 (SV40) large T (LgT) and small t proteins and androgen receptor, but these cells are unable to form anchorageindependent colonies 23 . However, the addition of H-Ras V12 promotes colony growth and adenocarcinoma when such cells are injected into mice 23 . DAB2IP ablation also promoted colony growth, indicating that DAB2IP loss transforms human prostate cells (Fig. 1c) . Notably, DAB2IP loss also triggered Ras, ERK and AKT activation (Fig. 1d) . These phenotypes were reversed by rescuing cells with a DAB2IP complementary DNA (Fig. 1e,f) .
DAB2IP loss promotes metastatic prostate cancer
When we orthotopically injected immortalized PrECs into mouse prostates, well-circumscribed, benign growths in the prostate developed (Fig. 1g) , as previously described 23 . The lesions had a low proliferative index, showed considerable apoptosis and regressed (9 of 15 regressed completely) ( Fig. 1g and Supplementary Fig. 2a,b) . However, mice injected with PrECs expressing oncogenic H-Ras V12 (15 of 15) or DAB2IP-specific short hairpin RNAs (15 of 15), developed prostate adenocarcinomas that expressed cytokeratin-8, prostatespecific antigen (PSA) and little tumor protein p63, similar to highgrade human tumors (Fig. 1g,h ). H-Ras V12 -expressing and DAB2IP-deficient tumors were highly proliferative, showed little apoptosis and grew with similar kinetics and to a similar maximum size (Fig. 1g,i,j and Supplementary Fig. 2b,c) . Mice injected with DAB2IP-reconstituted cells were similar to controls; most lesions regressed in 45 d, were small in size, or both ( Fig. 1g and Supplementary Fig. 2c) .
However, whereas H-Ras V12 -driven tumors remained noninvasive and never disseminated, all DAB2IP-deficient tumors were invasive and metastatic ( Fig. 2 and Supplementary Fig. 2d ). These tumors invaded the hip, lumbar muscle and bladder (Fig. 2b) 24 . We observed metastases starting at 45 d after injection in liver, proximal and distal lymph nodes, Fig. 2 ). The first column of images represents prostate tissue from a mouse in which a control lesion had regressed. The second column of images is from a small control lesion. The last column is from a prostate in which a 'rescued' lesion had regressed. seminal vesicles, testes and vas deferens ( Fig. 2c and Supplementary  Fig. 2d ). The metastases were derived from PrECs, as confirmed by SV40 LgT antigen immunostaining and sequenome-based single nucleotide polymorphism genotyping (Fig. 2c,d and Supplementary Fig. 3a) , and we never observed metastases from cells rescued with DAB2IP. We could readily detect DAB2IP-deficient tumor cells throughout the lymphatic and blood vessels, implicating both vessel systems in metastasis (Fig. 2d) . Mice also developed thromboemboli, a life-threatening complication observed in a subset of individuals with prostate cancer (Supplementary Fig. 3b ) 25 . The metastatic potential of these tumors can be best appreciated by Xenogen imaging (Fig. 2e) . Mice harboring DAB2IP-deficient tumors showed reduced survival compared to those with H-Ras V12 -expressing tumors ( Fig. 2f ; P = 0.03, Mann-Whitney U test). Thus, DAB2IP suppression promotes prostate tumorigenesis and uniquely triggers metastasis.
RasGAP activity partially underlies DAB2IP function
Because DAB2IP is a RasGAP, we investigated whether aberrant Ras activation was responsible for these phenotypes. We expanded our analysis to include metastatic human prostate cancer cells in which DAB2IP is epigenetically silenced (PC-3 cells), to more directly assess the effects of DAB2IP loss in human cancer 21 . PC-3 and DAB2IP-deficient PrEC cells were reconstituted with wild-type DAB2IP or a GAP activity-deficient point mutant. Wild-type DAB2IP had subtle effects on the proliferation of these cell lines in vitro, indicating that the re-introduction of physiological amounts of DAB2IP does not, by itself, induce a growth arrest ( Supplementary Fig. 4 ). DAB2IP proteins were equivalently expressed and recapitulated endogenous expression (Fig. 3a,b) . Wild-type DAB2IP reduced Ras-GTP, phosphorylated ERK (pERK) and pAKT amounts, whereas the catalytically inactive RasGAP mutant (DAB2IP-R289L) did not suppress these effectors (Fig. 3b) .
Mice injected with PC-3 cells developed metastatic prostate cancer ( Fig. 3c-e) . Wild-type DAB2IP significantly suppressed tumor development ( Fig. 3d ; P = 3 × 10 −8 , Mann-Whitney U test) and metastasis (Fig. 3c,e) ; however, DAB2IP-R289L was unable to suppress tumor growth, indicating that RasGAP activity is essential for its tumorsuppressive function ( Fig. 3c,d ; P = 0.71). Nevertheless, this mutant partially suppressed metastasis; only three of six mice developed metastases, and those that did had fewer metastases than mice injected with PC-3 cells lacking DAB2IP ( Fig. 3e ; P = 0.0083). We confirmed these findings with PrECs (Fig. 3f,g ). These results suggest that other regions of DAB2IP harbor metastasis-suppressing activity. 
DAB2IP regulates epithelial-to-mesenchymal transition
Notably, DAB2IP ablation in PrECs also induced an epithelial-tomesenchymal transition (EMT), a dynamic cellular process thought to underlie metastasis by promoting invasion, intravasation and extravasation [26] [27] [28] . DAB2IP loss promoted an increase in the expression of the mesenchymal markers vimentin, twist and fibronectin and a concomitant reduction in the expression of membrane-bound E-cadherin ( Fig. 3h and Supplementary Fig. 5 ) 29 . DAB2IP suppression also enhanced invasion (Supplementary Fig. 5a ). EMT occurred synchronously within 96 h and was not caused by the outgrowth of a specialized subset of cells (Supplementary Fig. 6 ). In contrast, H-Ras V12 was a much weaker regulator of EMT (Fig. 3h) .
We also observed EMT in vivo, as indicated by vimentin expression, which we observed in cells at the edge of these highly metastatic lesions (Fig. 3i) . We observed this expression pattern in every tumor examined (n = 12), and the vimentin was present in tumor cells, not stroma, as the antibody that we used exclusively recognizes human protein. Similar findings have been described in a metastatic breast cancer model and support the hypothesis that environmental cues contribute to EMT and metastasis 28, 30 . H-Ras V12 -expressing tumors never showed evidence of EMT (Fig. 3i) , supporting the hypothesis that distinct effects of DAB2IP loss on EMT underlie metastasis.
DAB2IP loss promotes metastasis via NF-B
Although Ras can promote EMT in some settings, a plethora of signals regulates this transition 27 . Of note, DAB2IP, in addition to its RasGAP activity, can suppress NF-κB in endothelial cells through a direct interaction with TRAF2, via a region distinct from the RasGAP domain 31 . Notably, NF-κB has a crucial role in EMT, and many EMT-associated genes, including TWIST1, are NF-κB targets 32 . NF-κB also promotes tumor progression and metastasis in other model systems 33 . Thus, we asked whether DAB2IP loss triggers EMT and metastasis by activating NF-κB.
Ectopic DAB2IP expression suppresses NF-κB in endothelial cells, but it was unknown whether DAB2IP loss would activate NF-κB in prostate cells 31 . DAB2IP ablation activated NF-κB (Fig. 4a) and increased expression of NF-κB transcriptional targets in PrECs ( Fig. 4b) 34 . Conversely, DAB2IP reconstitution suppressed NF-κB and target genes in PC-3 cells (Fig. 4a,c) . A point mutant in the period-like domain of DAB2IP that prevents TRAF2 binding (S604A) is defective in suppressing NF-κB activity in endothelial cells 31 . DAB2IP-S604A did not effectively inhibit NF-κB, but it still suppressed Ras ( Supplementary Fig. 7a,b) . This mutant was also defective in suppressing invasion and EMT, suggesting that NF-κB mediates these phenotypes in response to DAB2IP loss ( Supplementary  Fig. 7) . We confirmed this hypothesis by introducing a dominant-negative inhibitor of κBα protein, referred to as the IκBα super repressor (IκBαSR), which suppressed NF-κB activity, invasion and EMT in both model systems ( Supplementary Fig. 5 and data not shown). However, consistent with the notion that Ras feeds into the NF-κB pathway 35 , the DAB2IP double mutant (R289L and S604A) was more defective in suppressing invasion, EMT and NF-κB, illustrating cooperativity between these two domains and downstream signals (Supplementary Fig. 7) .
Notably, the DAB2IP-S604A mutant, which effectively suppressed Ras but not NF-κB, inhibited primary tumor growth, supporting the conclusion that Ras has a key role in tumor initiation ( Fig. 4d-g ; P = 1.65 × 10 −7 , Mann-Whitney U test). However, although the tumors were small, five of ten mice developed metastases, suggesting that aberrant NF-κB activity promoted dissemination (Fig. 4f,g) . Accordingly, the IκBαSR had no effect on primary tumor development (Fig. 4e,g ) but significantly suppressed metastasis (Fig. 4f,g ; P = 0.005). The DAB2IP double mutant (R289L and S604A) did not suppress primary tumor development (P = 0.48) or metastasis (P = 0.31) (Fig. 4e-g ). We observed similar results in the PrEC model (Fig. 4h,i) .
We conclude that DAB2IP loss induces the activation of Ras and NF-κB in prostate cancer. Ras is essential in primary tumor growth, whereas NF-κB drives metastasis. Notably, we found that whereas both H-Ras V12 expression and DAB2IP loss activated ERK and Control cDNA AKT in prostate tumors, NF-κB was activated exclusively in DAB2IP-deficient tumors, as indicated by the nuclear rather than cytoplasmic staining of NF-κB in these cells, supporting the conclusion that DAB2IP has distinct effects on NF-κB ( Fig. 4j and Supplementary Fig. 8a) . Accordingly, we also observed an enhanced inflammatory response in DAB2IP-deficient tumors (Supplementary Fig. 8b ). These observations challenge the concept that Ras and NF-κB exist in a simple linear pathway in this tumor type.
DAB2IP is a major EZH2 target
Thus far, our data identify a signaling cascade that drives metastatic disease and provide a tractable model system to interrogate the involvement of other genes in metastasis. Another gene implicated in metastatic prostate cancer is EZH2, which encodes the histone methyltransferase component of the polycomb-repressive complex-2 and regulates epigenetic gene silencing 36 . EZH2 is overexpressed in many tumor types, and its expression correlates with tumor grade 36 . EZH2 was also identified as the most differentially upregulated gene in metastatic prostate cancer 37 ; however, EZH2 has never been shown to drive metastasis, thus a causal role for EZH2 in this process remains to be established.
Over 250 polycomb-repressive complex-2 targets have been identified, including DAB2IP (refs. 22,38,39) . Therefore, we asked whether EZH2 could induce metastatic prostate cancer and investigated the potential contribution of DAB2IP silencing in EZH2-driven phenotypes. Notably, ectopic EZH2 expression promoted invasive prostate adenocarcinoma and metastasis to proximal and distal lymph nodes, liver and spleen ( Fig. 5a and Supplementary Table 1) . Like DAB2IP-deficient tumors, EZH2-driven tumors were detectable in lymphatic and blood vessels, and mice with these tumors developed thromboemboli (Fig. 5a) .
The observation that EZH2 overexpression phenocopies DAB2IP loss suggested that DAB2IP might be a key target of EZH2 in metastatic prostate cancer. EZH2 suppressed DAB2IP protein and messenger RNA expression in PrECs (Fig. 5b,c) , as previously observed in other cell lines 21 . Chromatin immunoprecipitation (ChIP) indicated that EZH2 bound the DAB2IP promoter (Fig. 5d) , indicating a direct transcriptional suppression of DAB2IP by EZH2. When we reconstituted EZH2-expressing cells with endogenous levels of DAB2IP, tumor growth was suppressed, and in 2 of 14 cases the tumors eventually regressed ( Fig. 5e; P = 4 × 10 −12 ) . Moreover, whereas we detected metastases in mice with EZH2-driven tumors within 8-12 weeks, DAB2IP prevented metastasis, even in mice surviving 1 year (Fig. 5f) . Accordingly, mice injected with DAB2IP-expressing cells survived longer than those injected with cells expressing EZH2 alone ( Fig. 5g ; P = 2.3 × 10 −4 , Yates correction). EZH2 also activated Ras, ERK, AKT and NF-κB, whereas DAB2IP reconstitution substantially suppressed activation (Fig. 5h,i) . Moreover, like DAB2IP-deficient tumors, metastatic EZH2-expressing lesions also underwent EMT at the invasive edge, which was prevented by DAB2IP reconstitution (Fig. 5h) . We also observed EMT in vitro (Supplementary Fig. 9 ). Finally, GAP domain (R289L) and period-like domain (S604A) mutants of DAB2IP had the same effects in EZH2-expressing cells as compared to DAB2IP-deficient PrEC and PC-3 cells on Ras signaling (Fig. 5i) and primary tumor growth and metastasis (Fig. 5j) . Thus EZH2 activates Ras and NF-κB by epigenetically suppressing DAB2IP, providing the molecular mechanism by which an epigenetic regulator activates these two major signaling pathways (Fig. 6a) .
DAB2IP is inactivated in human prostate cancer DAB2IP deletions have not been reported in human tumors; however, our data suggested that epigenetic suppression might represent a key mechanism of DAB2IP loss in human prostate cancer. Although DAB2IP has been shown to be a target of EZH2 in a few prostate cancer cell lines 21 , its expression has not been examined in human tumors. We confirmed the specificity of the DAB2IP-specific antibody (Fig. 6b) and performed immunohistochemical analysis on tissue microarrays containing 589 specimens from 117 individuals with prostate cancer. Normal basal and secretory cells expressed high amounts of DAB2IP (Fig. 6c-f) . By contrast, the majority of prostatic intraepithelial neoplasias and adenocarcinomas showed weak or no DAB2IP expression, which was often restricted to stroma in these biopsies ( Fig. 6c-f ; Kruskal-Wallis test, P = 1.8 × 10 −27 ). The low expression of DAB2IP can be appreciated in sections containing both normal and cancerous tissue (Fig. 6c) . Notably, DAB2IP expression inversely correlated with Gleason grade ( Fig. 6f ; Kruskal-Wallis, P = 0.001). Finally, among 81 subjects for whom clinical information was available, we found that DAB2IP expression was significantly lower in subjects with a poor prognosis, as measured by a shorter time to elevated blood concentrations of PSA (univariate Cox regression analysis: hazard ratio, 0.51; 95% confidence interval, 0.2-0.9; P = 0.03). Taken together, these results support a causal role for DAB2IP loss in human prostate cancer progression.
To investigate whether DAB2IP suppression in prostate cancer is caused by EZH2-mediated transcriptional silencing, we examined DAB2IP and EZH2 expression in Oncomine data sets 40 . Consistent with the results of our immunohistochemical analyses, DAB2IP mRNA levels were lower in prostate cancer compared to normal prostate tissue and decreased with increasing tumor grade ( Fig. 6g; Student's t test r = 7.181, P = 2 × 10 −7 ). We confirmed these results with three additional datasets [40] [41] [42] [43] . By comparing DAB2IP and EZH2 in individual tumors and metastases, we also found that DAB2IP levels inversely correlated with EZH2 levels ( P value (two-tailed) = 0.0463) 37 . Analysis of the distribution of R values from these data indicated that DAB2IP ranks in the top 4.5% of inversely correlated genes, as compared to EZH2 ( Supplementary  Fig. 10 ). Collectively, these observations demonstrate that EZH2 and DAB2IP exist in a linear pathway that, when deregulated, promotes metastatic prostate cancer.
DISCUSSION
If detected early, prostate cancer is curable; however, there are no effective therapies for metastatic disease. The current treatment for recurrent prostate cancer is surgical or medical castration. However, patients ultimately relapse and develop androgen-independent, metastatic tumors 44 . Therefore there is a considerable gap in our understanding of the mechanisms that underlie prostate cancer progression, metastasis and the development of effective therapies. This knowledge deficit is, in part, due to the lack of tractable model systems. Genetically engineered mouse models have helped define genes involved in tumor initiation and aspects of tumor progression; however, few models develop metastases, and, in those that do, it is unclear which genes drive this transition 45, 46 . Thus, orthotopic models represent a platform that can be used in a more high-throughput fashion for gene discovery, in particular for metastasis, which requires numerous prerequisite alterations. In this study we have identified DAB2IP as a regulator of metastatic prostate cancer. To our knowledge, no other gene has been shown to have a direct causal role in driving prostate cancer metastasis, underscoring the importance of this finding and the utility of this model.
These studies also provide insight into mechanisms that regulate tumor initiation versus metastasis. Specifically, DAB2IP loss promotes primary tumor growth by activating Ras and drives metastasis through NF-κB, serving as a signaling scaffold to coordinately regulate these two prominent oncogenic pathways (Fig. 6a) . Although Ras and NF-κB are known to be activated in advanced prostate cancer, the genetic alterations that confer activation are largely unknown [3] [4] [5] [6] 47 . Our findings reveal a molecular mechanism by which these two pathways can be activated in prostate cancer.
In some settings, Ras can promote NF-κB activation via its effects on the Ras-related protein RalB and the TANK-binding kinase-1 (refs. 47,48) ; however, here we report that Ras is not sufficient to stimulate NF-κB in prostate tumors. Although these observations seem contradictory, a mutation in the GAP domain of DAB2IP enhances the effects of a mutation in the period-like domain (on NF-κB activity), consistent with a cooperative role for Ras in this pathway. NF-κB is regulated by the integrated output of many signals, which may be differentially limiting in different tumor types. The data presented here suggest that DAB2IP is a crucial guardian of the NF-κB pathway in prostate tissue.
Finally, these studies suggest that epigenetic suppression of DAB2IP by EZH2 is a major mechanism of its inactivation in human prostate cancer. Of note, although EZH2 is highly expressed in advanced and metastatic prostate cancer 37 , it has never been shown to induce metastasis, leading to the unresolved question of whether EZH2 upregulation is a marker or driver of metastasis 49 . Our studies establish a causal role for EZH2 in driving metastasis and identify DAB2IP as a key target in this process among numerous target genes, although certainly others may contribute. These observations have major therapeutic implications. Because EZH2 is an enzyme, it has been proposed to be a potential therapeutic target 36 . Our data underscore the utility of developing EZH2 inhibitors, as such agents might suppress both Ras and NF-κB-proteins that have proven difficult to target directly-in prostate cancer. These findings also support the possibility that such inhibitors might affect primary tumors and metastatic lesions.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
